Medtech’s New Normal - C-Suite Challenges

A “new normal” in medtech has gained traction as the world has changed over the past year since the onset of the pandemic in Q1 2020. C-Suite priorities should be reexamined and fine-tuned to coincide with the new normal we’re likely to continue experiencing moving forward into 2021, and for the February edition of MPO Magazine we were asked to contribute our thoughts on the subject.

“The same matters took center stage in 2020, with certain market opportunities actually enhanced by the health crisis (telemedicine and digital health, most notably). These particular segments will experience significant growth this year as COVID-19 continues to force a physical divide between doctors and patients.

Although a “new normal” has emerged in medtech—the virus will certainly loom large over the industry for quite some time—many of the usual C-Suite management topics that are key to organizational success will remain the same this year, though they’ll have to be regularly fine-tuned. Priorities are likely to include “organic” functional disciplines (i.e., sales and marketing, supply chain, regulatory, manufacturing, and employee engagement) as well as inorganic strategies for properly timing potential M&A deals.”

In the full article, we cover changes that have taken place across sales, marketing, manufacturing, HR, supply chains and the ever-changing regulatory environment.

“Whether companies continue their growth in 2021 organically or inorganically, there will be challenges to overcome—financially, statutorily, and administratively. But the rewards will surely be well worth the effort.”

To read the full article, click below: